Comparing the response of triple therapy and conventional treatment in male congenital hypogonadotropic hypogonadism: a randomized controlled trial
Triple therapy (hCG + FSH + testosterone) cut the median hCG dose needed by 17% but didn't significantly improve spermatogenesis rates in 45 CHH men
Journal: Frontiers in Endocrinology | Published: 2026-04-01 | Type: Randomized Controlled Trial | PMID:41993983Authors: Konsam Biona Devi et al. (Department of Endocrinology, PGIMER, Chandigarh, India)
Funding/COI: Not listed. Authors declared no commercial or financial conflicts of interest.
Summary
This single-center RCT from northern India tested whether adding exogenous testosterone to the standard hCG + FSH regimen for congenital hypogonadotropic hypogonadism (CHH) would accelerate virilization and reduce gonadotropin requirements. The headline result is a statistically significant reduction in hCG dose at the point of spermatogenesis induction (7,500 vs. 9,000 IU/week, p=0.016). The spermatogenesis rate itself — the primary outcome — was not significantly different across groups (84.6% vs. 69.2% vs. 75%, p=0.648). Quality-of-life scores improved substantially in the triple therapy arm, but open-label design makes those subjective findings unreliable.
Claims
Spermatogenesis achieved in 76.3% of all participants (29/38 who completed follow-up), with rates of 84.6% (Group A, triple therapy), 69.2% (Group B, hCG+FSH), and 75% (Group C, sequential hCG then FSH) — difference not significant (p=0.648)
Median hCG dose at spermatogenesis was 7,500 IU/week in Group A vs. 9,000 IU/week in Groups B and C (p=0.016) — the only statistically significant primary finding
Median time to spermatogenesis: 12 months in Groups A and B, 15 months in Group C — not significant (p=0.345)
Median total sperm concentration achieved: 8 × 10⁶/mL (range 2.8–17.3); motility 20%; normal morphology 50%
Group A showed a 314.3% increase in body hair score, 178.3% improvement in sexual desire (SDI-2), and 75.2% improvement on qADAM quality-of-life scale at one year
Predictors of spermatogenesis: ultrasound testicular volume ≥1.97 mL (sensitivity 86.2%, specificity 62.5%); hCG dose ≥9,000 IU/week (sensitivity 79.3%, specificity 87.5%); inhibin B ≥66.8 pg/mL (sensitivity 92.6%, specificity 100%)
AMH target of 7.4 ng/mL was used to titrate hCG in Group A; median AMH achieved was 3.5 ng/mL
Study Quality
This is a registered RCT (CTRI/2022/05/042795) from a tertiary care center in India, which is an appropriate design for this question. The 1:1:1 allocation used permuted block randomization. Sample size was calculated with 80% power and a non-inferiority margin of 20%, arriving at 14 per group — the authors enrolled 15 per group to account for attrition, which was reasonable. Seven participants (15.5%) were lost to follow-up, reducing evaluable participants to 38. The analysis appears to be per-protocol rather than intention-to-treat, which inflates apparent success rates.
The trial is open-label — participants and clinicians knew which arm they were in. This is acknowledged as a limitation. For hard biological endpoints like sperm count it matters less; for the extensive subjective QoL scoring (BHS, SDI-2, PDS, qADAM) it matters a great deal. The impressive-looking virilization and QoL numbers from Group A cannot be taken at face value given the absence of blinding.
Red Flags
Underpowered for the primary outcome. With 13–15 evaluable participants per group, the trial lacks power to detect meaningful differences in spermatogenesis rates. The non-significant p=0.648 is unsurprising given n=38 total.
Open-label design introduces performance and detection bias in all subjective endpoints, which constitute most of the QoL claims.
Single center, limiting generalizability.
Comprehensive genetic testing not performed in all participants due to financial constraints — the CHH cohort may be heterogeneous.
Per-protocol analysis with 15.5% loss to follow-up; ITT results not reported.
Inhibin B and AMH as monitoring targets are novel and insufficiently validated — the AMH target of 7.4 ng/mL was derived from a single prior study's interim results.
The QoL improvements (314% BHS increase, etc.) are presented without accounting for expected natural progression during any treatment for untreated CHH men in their mid-twenties.
Strengths
Genuine RCT with prospective registration
No industry funding and declared absence of COI
Multiple validated instruments to quantify virilization and QoL
Provides a statistically robust predictor analysis (Inh B ≥66.8 pg/mL has high sensitivity and perfect specificity for spermatogenesis)
One of few RCTs directly comparing these three regimens head-to-head
Study duration (May 2022 – March 2024) is adequate for the endpoint measured
Verdict
The one credible result here is that adding testosterone to hCG + FSH lets you use less hCG to achieve spermatogenesis — a modest but clinically meaningful finding if replicated. Everything else is either underpowered noise (the spermatogenesis rate comparison) or compromised by open-label bias (the QoL bonanza in Group A). The paper is worth reading for the inhibin B threshold data and the predictor analysis; the QoL claims need a blinded, larger trial before they mean anything. The authors are appropriately self-critical about sample size and blinding — the conclusions are more measured than the abstract implies.